A modified somatostatin peptide delivers radioactivity to nasopharyngeal tumors more effectively than DOTATATE, potentially extending PRRT to a new cancer type.
Outperformed DOTATATELNC1010 showed higher tumor uptake, longer retention, and greater tumor growth inhibition than the current standard PRRT peptide in nasopharyngeal cancer models
What the researchers found
A new somatostatin receptor-targeting radioactive peptide, [177Lu]Lu-LNC1010, showed higher tumor uptake, longer retention, and greater tumor growth inhibition than the standard [177Lu]Lu-DOTATATE in nasopharyngeal carcinoma (NPC) cell and mouse models. The enhanced performance comes from an Evans blue-binding moiety and PEG linker added to the DOTATATE backbone, which extends circulation time. In a proof-of-concept human case, PRRT with LNC1010 achieved favorable therapeutic results with negligible side effects in a metastatic NPC patient.
Why it matters
Peptide receptor radionuclide therapy (PRRT) has been revolutionary for neuroendocrine tumors but hasn't been applied to other cancers. This study shows SSTR2 is expressed on nasopharyngeal carcinoma and that a modified somatostatin peptide can deliver radioactivity directly to these tumors. If validated, this could extend PRRT — one of the most successful peptide-based cancer treatments — to a completely new cancer type.
The numbers in context
Higher tumor uptake and longer retention than DOTATATE in xenografts; greater tumor growth inhibition; 1 pilot clinical patient treated with favorable response
How the study worked
Multi-phase study: in vitro binding assays on C666-1 NPC cells, PET/SPECT imaging and biodistribution studies in C666-1 xenograft mouse models comparing LNC1010 vs DOTATATE, preclinical PRRT efficacy studies in mice, and a single-patient proof-of-concept clinical pilot.
Who was studied
C666-1 NPC cell line and xenograft mouse models, plus 1 human patient with metastatic nasopharyngeal carcinoma
What this study cannot tell us
Preclinical data comes from a single NPC cell line (C666-1). The human clinical evidence consists of only one patient — far too small for clinical conclusions. Long-term safety and efficacy data are lacking. Kidney retention of radioactive peptides is a known concern not fully addressed.
How to read the evidence
Strong preclinical data across multiple modalities (in vitro, imaging, biodistribution, therapeutic efficacy), but only one human patient treated. This is early-stage translational research requiring clinical trials for validation.
When this study was published
Published in 2024, this represents cutting-edge translational research extending PRRT technology to a new cancer indication.
The bigger picture
PRRT has been limited to neuroendocrine tumors because those are the cancers known to express somatostatin receptors at high levels. This study expands the map by showing nasopharyngeal carcinoma also expresses SSTR2, and that an engineered peptide can exploit this for targeted radiotherapy. If confirmed in larger trials, it could open PRRT to a much wider range of cancers.
Questions still open
- What percentage of nasopharyngeal carcinomas express enough SSTR2 for effective PRRT targeting?
- How does the kidney radiation dose from LNC1010 compare to standard DOTATATE?
- Could LNC1010 be combined with immunotherapy for synergistic effects in NPC?
Common questions
What is peptide receptor radionuclide therapy (PRRT)?
How is LNC1010 different from regular DOTATATE?
Read the original research
Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma.
European journal of nuclear medicine and molecular imaging, 52(1), 247-259
Citation
Chen, Jianhao; Pang, Yizhen; Liao, Xiyi; Zhou, Yangfan; Luo, Qicong; Wu, Hua; Zuo, Changjing; Zhang, Jingjing; Lin, Qin; Chen, Xiaoyuan; Zhao, Liang; Chen, Haojun. (2024). Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma.. European journal of nuclear medicine and molecular imaging, 52(1), 247-259. https://doi.org/10.1007/s00259-024-06874-9